Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pathology

The Biology of KLA and How It Differs from Other Conditions

At a Glance

Kaposiform lymphangiomatosis is distinguished from related lymphatic disorders by its clinical pattern, thoracic involvement, imaging, and pathology. NRAS Q61R can support the diagnosis, but a negative test does not rule out KLA and a positive result is not diagnostic by itself.

Understanding the biology of Kaposiform lymphangiomatosis (KLA) is like solving a genetic puzzle. For many years, KLA was confused with other lymphatic conditions because they look similar on a standard X-ray or under a microscope. Today, scientists have identified specific genetic associations and clinical patterns that help doctors distinguish KLA from its close relatives [1][2].

The Genetic Association: NRAS Q61R

The most significant breakthrough in KLA research is the discovery of the NRAS Q61R mutation in many patients [1]. This is a somatic mutation, meaning it occurred in the affected tissue during development; it is not inherited from parents in a way that passes down [1][3].

This mutation acts like a “broken switch” that is permanently stuck in the “on” position. It activates the RAS-MAPK pathway, a signaling network that tells cells when to grow and move [4][5]. In KLA, this causes lymphatic endothelial cells to behave abnormally, leading to the formation of disorganized, leaky vessels and clusters of specialized spindle cells [6][2].

Important Note: While NRAS Q61R is a strong marker for KLA, not every case has a detectable variant. Sometimes the tissue sample is too small, or the assay is not sensitive enough. A negative test does not exclude a KLA diagnosis, and a mutation result alone does not establish the diagnosis or dictate treatment without the full clinical picture.

Differentiating KLA from Similar Conditions

Because KLA involves multiple systems, it is often part of a group called Complex Lymphatic Anomalies (CLAs) [7]. These conditions overlap, and distinguishing them requires expert imaging and pathology.

KLA vs. Generalized Lymphatic Anomaly (GLA)

KLA and GLA both involve abnormal lymph vessels throughout the body, but they often have key differences:

  • Genetics: While KLA is primarily associated with NRAS mutations, alterations in the PIK3CA gene are found in a subset of GLA cases [8]. However, this is not an absolute rule, and there is genetic overlap.
  • Thoracic Involvement: KLA is often much more aggressive in the chest. It frequently causes hemorrhagic (bloody) fluid buildup and lung disease, which are less typical in GLA [9][10].
  • Spindle Cells: KLA is defined by the presence of sparse clusters of spindle cells in the tissue, which are not typically found in GLA [2].

KLA vs. Gorham-Stout Disease (GSD)

GSD is sometimes called “disappearing bone disease” because of how it affects the skeleton [11].

  • Bone Pattern: In GSD, bone loss is typically progressive and contiguous, meaning it moves from one bone to the next and destroys the outer “shell” (cortex) of the bone [11][12]. In KLA, bone lesions are usually multifocal (appearing in several spots at once) and do not typically cause the bone to “disappear” in the same way [12].
  • Biological Driver: GSD has been associated with different mutations, including KRAS or certain gene fusions like ROS1, rather than the NRAS mutation typically seen in KLA [13][14].

KLA vs. Kaposiform Hemangioendothelioma (KHE)

KHE is a vascular tumor that can also cause severely low platelets and consumptive coagulopathy (Kasabach-Merritt phenomenon), so low platelets alone do not distinguish them.

  • Architecture: KHE typically forms dense, well-defined nodules of spindle cells surrounded by scar-like tissue (fibrosis) [10][15]. In contrast, KLA features sparse, poorly defined clusters of spindle cells scattered throughout malformed lymph vessels [10].
  • Systemic Reach: While KHE can be infiltrative and multifocal, KLA is deeply characterized by systemic thoracic disease (lungs, pleura, pericardium) [10].

Why the Distinction Matters

Identifying the specific genetic pathways and clinical patterns allows your medical team to move toward targeted options [4]. For example, if the RAS-MAPK pathway is highly active, doctors may discuss off-label use of medications like MEK inhibitors (trametinib) [4][16]. Understanding these biological differences is an ongoing process guided by your expert team.

Common questions in this guide

What does an NRAS Q61R result mean in KLA?
NRAS Q61R is a change found in the affected tissue in many people with KLA, rather than a mutation inherited from a parent. It can keep the RAS-MAPK cell-growth pathway switched on and may support a KLA diagnosis. The result must be interpreted with the clinical findings, imaging, and pathology.
Can a negative NRAS Q61R test rule out KLA?
No. A test can be negative when the sample is too small or the method cannot detect a low-level change, and not every KLA case has a detectable variant. Doctors use the full clinical, imaging, and pathology picture rather than relying on this test alone.
How is KLA different from generalized lymphatic anomaly?
Both can involve abnormal lymphatic vessels throughout the body, and their genetic findings can overlap. KLA more often has severe chest involvement, including lung disease and bloody fluid, and its tissue may show sparse spindle-cell clusters; these findings are less typical of generalized lymphatic anomaly. PIK3CA changes can occur in generalized lymphatic anomaly, but genetics alone does not separate every case.
How do KLA bone lesions differ from Gorham-Stout disease?
Gorham-Stout disease usually causes progressive, contiguous loss of bone that can destroy the outer bone layer. KLA more often causes multifocal bone lesions that appear in several areas and do not typically make the bone disappear in the same pattern. Imaging specialists interpret these patterns alongside other findings.
How do pathologists distinguish KLA from kaposiform hemangioendothelioma?
KLA typically has sparse, poorly defined spindle-cell clusters scattered among malformed lymphatic vessels. Kaposiform hemangioendothelioma more often forms dense, well-defined spindle-cell nodules surrounded by scar-like tissue. Low platelets can occur with kaposiform hemangioendothelioma, so that finding alone cannot distinguish the two conditions.
Could a MEK inhibitor be considered for KLA?
Specialists may discuss an off-label MEK inhibitor such as trametinib when the RAS-MAPK pathway appears active. A mutation result alone does not determine treatment, and decisions depend on the full clinical, imaging, pathology, and treatment context.

Get notified when new evidence is published on Kaposiform lymphangiomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    A somatic activating NRAS variant associated with kaposiform lymphangiomatosis.

    Barclay SF, Inman KW, Luks VL, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2019; (21(7)):1517-1524 doi:10.1038/s41436-018-0390-0.

    PMID: 30542204
  2. 2

    Kaposiform Lymphangiomatosis: Pathologic Aspects in 43 Patients.

    Perez-Atayde AR, Debelenko L, Al-Ibraheemi A, et al.

    The American journal of surgical pathology 2022; (46(7)):963-976 doi:10.1097/PAS.0000000000001898.

    PMID: 35385405
  3. 3

    Detection of NRAS mutation in cell-free DNA biological fluids from patients with kaposiform lymphangiomatosis.

    Ozeki M, Aoki Y, Nozawa A, et al.

    Orphanet journal of rare diseases 2019; (14(1)):215 doi:10.1186/s13023-019-1191-5.

    PMID: 31511039
  4. 4

    MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

    Alharbi S, Wagner A, Merkle S, et al.

    Pediatric blood & cancer 2026; (73(3)):e70002 doi:10.1002/1545-5017.70002.

    PMID: 41496696
  5. 5

    Lyve1-Driven NrasQ61R Causes Edema, Enlarged Lymphatic Vessels, and Hepatic Vascular Defects in Embryonic Mice.

    McDaniel CG, Fox D, Pastura P, et al.

    Pediatric blood & cancer 2025; (72(3)):e31492 doi:10.1002/pbc.31492.

    PMID: 39723841
  6. 6

    Human Lymphatic Endothelial Cells Expressing NRASQ61R Model Characteristics of Kaposiform Lymphangiomatosis.

    Fox DA, McDaniel CG, Pastura P, Le Cras TD

    Pediatric blood & cancer 2025; (72(11)):e31984 doi:10.1002/pbc.31984.

    PMID: 40879319
  7. 7

    Updated Classification of Vascular Anomalies. A living document from the International Society for the Study of Vascular Anomalies Classification Group.

    Goldenberg DC, Vikkula M, Penington A, et al.

    Journal of vascular anomalies 2025; (6(2)) doi:10.1097/JOVA.0000000000000113.

    PMID: 40636925
  8. 8

    Somatic activating mutations in PIK3CA cause generalized lymphatic anomaly.

    Rodriguez-Laguna L, Agra N, Ibañez K, et al.

    The Journal of experimental medicine 2019; (216(2)):407-418 doi:10.1084/jem.20181353.

    PMID: 30591517
  9. 9

    Potential biomarkers of kaposiform lymphangiomatosis.

    Ozeki M, Nozawa A, Kawamoto N, et al.

    Pediatric blood & cancer 2019; (66(9)):e27878 doi:10.1002/pbc.27878.

    PMID: 31207041
  10. 10

    Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.

    Ji Y, Chen S, Peng S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):165 doi:10.1186/s13023-019-1147-9.

    PMID: 31277673
  11. 11

    Clinical Features and Prognosis of Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and Gorham-Stout Disease.

    Ozeki M, Fujino A, Matsuoka K, et al.

    Pediatric blood & cancer 2016; (63(5)):832-8 doi:10.1002/pbc.25914.

    PMID: 26806875
  12. 12

    [Complicated lymphatic anomaly: a clinicopathological analysis of four cases].

    Pan BJ, Zhao DC, Zhou WX, Feng RE

    Zhonghua bing li xue za zhi = Chinese journal of pathology 2022; (51(11)):1147-1151 doi:10.3760/cma.j.cn112151-20220825-00728.

    PMID: 36323545
  13. 13

    Trametinib inhibits lymphatic vessel invasion of bone in a mouse model of Gorham-Stout disease.

    McCarter AL, Dellinger MT

    Journal of vascular anomalies 2023; (4(4)) doi:10.1097/jova.0000000000000070.

    PMID: 38737531
  14. 14

    NRAS mutation in a central conducting lymphatic anomaly and PPFIBP1::ROS1 fusion in a Gorham-stout disease patient.

    Yang G, Ren H, Wang J, et al.

    Human molecular genetics 2026; (35(16)) doi:10.1093/hmg/ddag070.

    PMID: 42544506
  15. 15

    Cellular variant of kaposiform lymphangiomatosis: a report of three cases, expanding the morphologic and molecular genetic spectrum of this rare entity.

    Allen-Rhoades W, Al-Ibraheemi A, Kohorst M, et al.

    Human pathology 2022; (122()):72-81 doi:10.1016/j.humpath.2022.02.010.

    PMID: 35202617
  16. 16

    Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

    Brown G, McNab S, Keogh S, et al.

    Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.

    PMID: 42639465

This page is for informational purposes only and does not constitute medical advice. Your specialist team should interpret KLA genetic testing, imaging, and pathology together before discussing treatment.